FOSL1 and non-small cell lung carcinoma: This study improved the Boolean implication networks to model multivariate CNV and gene expression profiles in NSCLC tumors and identified the immune-omics network of CD27, PD1, and PDL1. Among the identified five prognostic genes, anti-human FRα (FOSL1) antibody-drug conjugate (MORAb-202) achieved robust antitumor response in patient-derived xenograft models [83] and a phase I clinical trial of FRα (FOSL1)-positive advanced solid tumors [84].